FDA Halts Aardvark Therapeutics Rare Disease Study

Aardvark Therapeutics Inc. (NASDAQ:AARD) said the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application for ARD-101, following the company’s previously disclosed voluntary program pause. ARD-101 is an...